You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Ozanimod hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for ozanimod hydrochloride and what is the scope of freedom to operate?

Ozanimod hydrochloride is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ozanimod hydrochloride has one hundred and sixty-eight patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for ozanimod hydrochloride
International Patents:168
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 12
Clinical Trials: 30
Patent Applications: 14
What excipients (inactive ingredients) are in ozanimod hydrochloride?ozanimod hydrochloride excipients list
DailyMed Link:ozanimod hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ozanimod hydrochloride
Generic Entry Date for ozanimod hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ozanimod hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Geert D'HaensPhase 4
I.R.C.C.S. Fondazione Santa LuciaPhase 4
Bristol-Myers SquibbPhase 3

See all ozanimod hydrochloride clinical trials

Pharmacology for ozanimod hydrochloride

US Patents and Regulatory Information for ozanimod hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-002 Mar 25, 2020 RX Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Bristol ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-001 Mar 25, 2020 RX Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Bristol ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-001 Mar 25, 2020 RX Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Bristol ZEPOSIA ozanimod hydrochloride CAPSULE;ORAL 209899-002 Mar 25, 2020 RX Yes No ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ozanimod hydrochloride

Country Patent Number Title Estimated Expiration
Hungary E050411 ⤷  Try for Free
European Patent Office 3470400 FORME CRISTALLINE DE L'OZANIMOD, FORME CRISTALLINE DE SON HYDROCHLORIDE ET SON PROCÉDÉ DE PRÉPARATION (CRYSTAL FORM OF OZANIMOD, CRYSTAL FORM OF HYDROCHLORIDE THEREOF, AND PREPARATION METHOD THEREFOR) ⤷  Try for Free
Malaysia 156381 NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS ⤷  Try for Free
South Korea 101781233 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ozanimod hydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2291080 132020000000124 Italy ⤷  Try for Free PRODUCT NAME: OZANIMOD O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE OZANIMOD CLORIDRATO(ZEPOSIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1442, 20200525
2291080 CA 2020 00047 Denmark ⤷  Try for Free PRODUCT NAME: OZANIMOD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER OZANIMODHYDROCHLORID; REG. NO/DATE: EU/1/20/1442 20200520
2291080 301065 Netherlands ⤷  Try for Free PRODUCT NAME: OZANIMOD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER OZANIMODHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/20/1442 20200525
2498610 PA2020533 Lithuania ⤷  Try for Free PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for Ozanimod Hydrochloride

Introduction

Ozanimod hydrochloride, marketed as Zeposia, is a significant player in the treatment of relapsing forms of multiple sclerosis (MS) and other autoimmune diseases. Here, we delve into the market dynamics and financial trajectory of this drug, highlighting its current market position, growth prospects, and economic implications.

Market Size and Growth

The global Ozanimod market is poised for substantial growth. As of 2024, the market size is estimated to be in the millions, with a compound annual growth rate (CAGR) of 6% projected from 2024 to 2031[1].

Regional Market Performance

North America

North America dominates the Ozanimod market, accounting for around 40% of the global revenue in 2024. This region is expected to grow at a CAGR of 4.2% from 2024 to 2031, driven by increasing incidences of autoimmune diseases, favorable reimbursement policies, and a strong healthcare infrastructure[1].

Europe

Europe is the fastest-growing region in the Ozanimod market, with a CAGR of 4.5% from 2024 to 2031. The growth is fueled by rising incidences of autoimmune diseases, a favorable regulatory environment, and growing investments in research and development[1].

Asia Pacific

The Asia Pacific region holds around 23% of the global revenue and is expected to grow at a CAGR of 8% from 2024 to 2031, making it a promising market for Ozanimod[1].

Latin America and Middle East & Africa

Latin America and the Middle East & Africa also contribute to the market, with CAGRs of 5.4% and 5.7%, respectively, from 2024 to 2031[1].

Driving Factors

Increasing Incidence of Autoimmune Diseases

The rising incidence of autoimmune diseases such as multiple sclerosis and inflammatory bowel disease is a key driver of the Ozanimod market. As these diseases become more prevalent, the demand for effective treatments like Ozanimod increases[1].

Favorable Regulatory Environment

A favorable regulatory environment in regions like Europe and North America supports the growth of the Ozanimod market. Regulatory approvals and positive clinical trial outcomes have bolstered confidence among healthcare providers and patients[1][5].

Research and Development

Ongoing research and development efforts are crucial for the market's growth. Clinical trials, such as the RADIANCE and SUNBEAM trials, have demonstrated the efficacy and safety of Ozanimod, further solidifying its position in the market[2][5].

Economic Evaluation

Cost-Effectiveness

Ozanimod is more effective but also more costly than some other disease-modifying therapies (DMTs). For instance, it has an incremental cost-effectiveness ratio (ICER) of $68,833 per quality-adjusted life-year (QALY) gained compared to Avonex, and $2.2 million compared to teriflunomide[3].

Pharmacoeconomic Analysis

Pharmacoeconomic analyses, such as those conducted by CADTH, highlight that while Ozanimod is more effective than some DMTs, it is often dominated by other treatments like alemtuzumab in terms of cost-effectiveness. However, its unique efficacy profile and patient preference for oral administration contribute to its market value[3].

Clinical Efficacy and Safety

Clinical Trials

Clinical trials have shown that Ozanimod demonstrates sustained efficacy in treating relapsing-remitting multiple sclerosis. The RADIANCE Part A trial, for example, showed that Ozanimod reduced the annualized relapse rate and the number of new or enlarging T2 lesions over a two-year period[2].

Safety Profile

Ozanimod has a favorable safety profile, with no unexpected safety signals emerging in clinical trials. The incidence of serious treatment-emergent adverse events is relatively low, making it a tolerable option for patients[2].

Market Segments

Research and Medical

The Ozanimod market is driven by both research and medical segments. Research efforts continue to bolster the market's growth trajectory, while the medical segment, driven by increasing diagnoses and treatment options, is a significant force behind the market's expansion[1].

Competitive Landscape

Ozanimod competes with other DMTs in the MS treatment market. While it is more effective than some competitors, it faces stiff competition from drugs like alemtuzumab, fingolimod, and cladribine, which are often more cost-effective[3].

Regulatory Approvals

Ozanimod received FDA approval for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting MS, based on the results of the SUNBEAM and RADIANCE trials[5].

Financial Implications

The financial trajectory of Ozanimod is influenced by its market size, growth rate, and cost-effectiveness. As the market expands, pharmaceutical companies are likely to invest more in marketing, research, and development to maintain and increase their market share.

Key Takeaways

  • Market Growth: The global Ozanimod market is expected to grow at a CAGR of 6% from 2024 to 2031.
  • Regional Dominance: North America and Europe are key regions driving the market growth.
  • Driving Factors: Increasing incidence of autoimmune diseases, favorable regulatory environment, and ongoing research and development.
  • Economic Evaluation: Ozanimod is more effective but more costly than some DMTs, with significant ICER values.
  • Clinical Efficacy and Safety: Demonstrated sustained efficacy and a favorable safety profile in clinical trials.
  • Market Segments: Driven by both research and medical segments.

FAQs

What is Ozanimod used for?

Ozanimod is used for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting MS[5].

What is the projected CAGR for the Ozanimod market from 2024 to 2031?

The Ozanimod market is projected to grow at a CAGR of 6% from 2024 to 2031[1].

Which regions dominate the Ozanimod market?

North America and Europe are the dominant regions in the Ozanimod market, with North America accounting for around 40% of the global revenue[1].

How does Ozanimod compare to other DMTs in terms of cost-effectiveness?

Ozanimod is more effective but more costly than some DMTs, with an ICER of $68,833 per QALY gained compared to Avonex and $2.2 million compared to teriflunomide[3].

What are the key drivers of the Ozanimod market?

The key drivers include increasing incidence of autoimmune diseases, a favorable regulatory environment, and ongoing research and development efforts[1].

What is the safety profile of Ozanimod?

Ozanimod has a favorable safety profile with no unexpected safety signals emerging in clinical trials, and a low incidence of serious treatment-emergent adverse events[2].

Sources

  1. Cognitive Market Research: Ozanimod Market Report.
  2. NCBI: Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized, double-blind, placebo-controlled phase 2 study.
  3. CADTH: Pharmacoeconomic Review Report for Ozanimod.
  4. FDA: PRODUCT QUALITY REVIEW(S) for Ozanimod.
  5. Cleveland Clinic: Ozanimod and Multiple Sclerosis.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.